Next Generation Sequencing Facilitates Quantitative Analysis of Transcriptomes and TCR repertoire in vaccinated PBMCs and tumors. Next Generation Sequencing Facilitates Quantitative Analysis of Transcriptomes and TCR repertoire in vaccinated PBMCs and tumors

In the clinical trial, we evaluated the immunological efficacy of the vaccination of GBM6-AD, a tumor-cell lysate, assisted with poly-ICLC in low grade glioma. To characterize the gene expression, subset proportions, and T-cell receptor (TCR) profile of T-cells in PBMCs, we analyzed pre- and post-neoadjuvant vaccinated PBMCs from four immunological responders (103-018, -26, -29, -51), using droplet-based 5’ single-cell RNA-sequencing (scRNA-seq) and single-cell T-cell receptor-sequencing (scTCR-seq) with 10x GENOMICS platform. Further, we analyzed the gene expression profiles in resected tumor specimens by bulk RNA-seq analyses. Overall design: Pre- and post-neoadjuvant vaccinated PBMCs from four immunological responders (103-018, -26, -29, -51), those were identified by mass cytometric analyses, were analyzed by scRNA-seq analyses. All of the available resected tumor specimens from both Arm 1 (neoadjuvant vaccination) and Arm 2 (control) were analyzed by bulk RNA-seq analyses